RxDoctor Payments Data

David Heiden, MD

Ophthalmology · San Francisco, CANPI 1053312108

Payments from drug & device makers

$2,335in general payments, 2019–2025

Across 52 payments — averaging $44.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$912
  • AbbVie$543
  • Biotissue Holdings Inc.$201
  • Ocular Therapeutix, Inc.$136
  • Amgen$106
  • Apellis Pharmaceuticals, Inc.$81
  • plus $357 from 11 others

What the payments were for

  • Food & beverage$1,42361%
  • Other$91239%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,335 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$99,739
Medicare patients
437
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost89$36,174
Restasis MultidoseCyclosporine39$24,452
RocklatanNetarsudil Mesylat/Latanoprost39$20,757
CombiganBrimonidine Tartrate/Timolol52$14,907
XiidraLifitegrast12$8,236
SimbrinzaBrinzolamide/Brimonidine Tart28$5,602
Difluprednate35$3,307
ZioptanTafluprost/Pf13$3,170
Travoprost14$2,426
Prednisolone Acetate35$2,214
Latanoprost166$1,442
ValacyclovirValacyclovir Hcl19$1,074
Timolol Maleate59$632
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha43$493
Brimonidine Tartrate18$463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis Multidose, Combigan$543$75,534180 claims
Aerie Pharmaceuticals, Inc.Rocklatan$24$20,75739 claims
Bausch & Lomb Americas Inc.Xiidra$47$8,23612 claims
AlconSimbrinza$52$5,60228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →